ClinicalTrials.gg
CompletedNCT01404169Updated Mar 8, 2017

A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease

A Phase 3 interventional study of E2020 and Placebo in Alzheimer's Type Dementia, sponsored by Eisai Limited. Completed at 32 sites in China. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2017-03-08.

Sponsored by Eisai Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Enrollment
6th of 58
260 · median 79
Started
2011
with 2 others
Phase 3
10 of 60
1 open now
Registered
34th of 60
by date
Lead sponsor
2 of 60
Eisai Limited

Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 6th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2011, is one of 10 in phase 3, and was the 34th registered.

Alzheimer Disease

3,968 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

The objective is to demonstrate that donepezil hydrochloride 10 mg/day has superior efficacy compared with placebo in cognitive function in Chinese subjects with severe Alzheimer's Disease.

03

Conditions studied

  • Alzheimer's Type Dementia

Keywords

  • Alzheimer Disease
  • Dementia
  • Delirium
  • Amnestic
  • Cognitive Disorders
  • Donepezil
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Tauopathies
  • Neurodegenerative Diseases
  • Mental Disorders
  • Cholinesterase Inhibitors
  • Enzy
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written (IC) will be obtained from the subject (if possible) or from the subject's legal guardian or legal representative prior to beginning screening activities.
  • Subject age range: male and female subjects 50 to 90 years of age, inclusive
  • Diagnosis: diagnostic evidence of probable Alzheimer's Disease (AD) consistent with , Fourth Edition, Text Revision (DSM-IV-TR) and National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
  • 1 to 12 inclusive, at both Screening and Baseline
  • SIB less than or equal to 90 and greater than or equal to 10 at both Screening and Baseline
  • Comorbid medical conditions must be clinically stable prior to Baseline, unless otherwise specified.

Exclusion criteria

Exclusion Criteria

  • Subjects with a known history of disorders that affect cognition or the ability to assess cognition, but are distinguishable from AD
  • Evidence of focal disease to account for dementia on any cranial image MRI or CT.
  • Subjects with dementia complicated by other organic disease or AD with delirium according to criteria
  • Subjects who cannot swallow or who have difficulty swallowing whole tablets, as tablets should not be broken or crushed
  • Illiteracy prior to AD
  • Subjects who are unwilling or unable to fulfill the requirements of the study
  • Treatment with another cholinesterase inhibitor and/or memantine in the 3 months prior to Screening
  • Subjects with a poor response (tolerability) to prior exposure to donepezil
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    1

    Drug: E2020

  • Placebo comparator
    2

    Drug: Placebo

Interventions

  • DrugE2020

    In titration period, donepezil 5-mg tablet will be taken orally once daily for 6 weeks, following donepezil 10 mg tablets taken orally once daily for 18 weeks in the maintenance period.

  • DrugPlacebo

    Placebo matched to donepezil 5 mg or 10 mg tablets taken orally once daily for 24 weeks.

06

What researchers measure

Primary outcomes

  1. The change in the total Severe Impairment Battery (SIB) score at Week 24

    All statistical tests will be conducted at the 0.05 level of significance (two-tailed). A positive outcome will be declared if for the primary efficacy endpoint as measured by the Severe Impairment Battery (SIB), the change from Baseline to Week 24 in the total SIB score last observation carried forward (LOCF) demonstrates superiority for donepezil 10 mg, compared with placebo.

    Time frame: 24 weeks

Secondary outcomes

  1. Clinician Interview-Based Impression of Severity (CIBIC)+ overall score at Week 24

    An ANCOVA with embedded Cochran-Mantel-Haenszel (CMH) test will be used with the CIBIC+ and center in the model. Overall change from Baseline in scores at Week 24 (LOCF) will be analyzed with the same model as the SIB.

    Time frame: 24 weeks

07

Study locations

32 sites
  • Beijing Anding Hospital
    Beijing, Beijing, China
  • Beijing Hospital
    Beijing, Beijing, China
  • Beijing Huilongguan Hospital
    Beijing, Beijing, China
  • Chinese PLA General Hospital
    Beijing, Beijing, China
  • Xuanwu Hospital Capital Medical University
    Beijing, Beijing, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing, China
  • Guangzhou Brain Hospital
    Guangzhou, Guangdong, China
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong, China
  • The People's Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi, China
  • Tongji Hospital, Tongji Medical College of HUST
    Wuhan, Hubei, China
  • Union Hospital, Tongji Medical college Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The First People's Hospital of YueYang
    Yueyang, Hunan, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
  • The Second Hospital of Shandong University
    Jinan, Shandong, China
  • The Affiliated Hospital of Medical College Qingdao University
    Qingdao, Shandong, China
  • Hushan Hospital affliated to Fudan University
    Shanghai, Shanghai, China
  • Renji Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai, China
  • Shanghai Changzheng Hospital
    Shanghai, Shanghai, China
  • Shanghai Ruijin Hospital
    Shanghai, Shanghai, China
  • Tangdu Hospital, The Fourth Military Medical University
    Xi'An, Shanxi, China
  • Xi'An Mental Health Center
    Xi'An, Shanxi, China
  • Xijing Hospital, The Fourth Military Medical University
    Xi'An, Shanxi, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan, China
  • First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
  • The Second Affiliated hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • The Second Affiliated Hospital to Nanchang University
    Nanchang, China
  • Nanjing Brain Hospital
    Nanjing Jiangsu, China
  • Tianjin Anding Hospital
    Tianjin, China
  • Tianjin People's Hospital
    Tianjin, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2011 to primary completion in Jul 2014, 34 months.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 34 months is below that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2011
First posted
Jul 27, 2011
StartActual
Sep 2011
Primary completionActual
Jul 2014
CompletionActual
Sep 2014
Last update
Mar 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01404169
Lead sponsor
Eisai Limited
Responsible party
Sponsor
First posted
Jul 27, 2011
Start date
Sep 2011
Primary completion
Jul 2014
Completion
Sep 2014
Last update
Mar 8, 2017

Study contacts

Naoki Kubota
study director · Neuroscience Clinical Development Section, Japan/Asia Clinical Research Product Creation Unit, Eisai Co., Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion